Recent Updates
Recently added Catalysts

SPECT

Phase 3

Parkinson Disease | Small molecule | Neurology |GE HealthCare Technologies Inc.|Last Updated: Nov 17, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment152
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04265209[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorPHASE3 COMPLETED 152Dec 1, 2021Aug 2, 2024Nov 17, 202516 France
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Sensitivity and specificity by visual analysis
The independent review committee will analyse the PET and SPECT images blindly. These analyses will be done by batch of 25 patients. Outcome will be assessed at the end of the study, an average of 2 years after first patient in.

Sensitivity and specificity of each imaging method on the diagnosis of normal or pathological examination on the visual analysis by 5 independent readers interpreting a minimum of 200 \[123I\]-FP/CIT SPECT per year, without knowing the clinical diagnosis.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
SPECT and PETOTHER\[123I\]-FP-CIT SPECT imaging procedure first, then \[18F\] LBT-999 PET Imaging procedure
PET and SPECTOTHER\[18F\] LBT-999 PET imaging procedure first, then \[123I\]-FP-CIT SPECT imaging procedure
Interventions
NameTypeDescription
SPECTDRUG\[123I\]-FP-CIT SPECT imaging procedure
PETDRUG\[18F\] LBT-999 PET imaging procedure
Unlock Study Design Details
Eligibility Criteria
Age Range35 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Patients aged 35 to 80 (male or female) * Patients: * suffering from an essential tremor as defined by Elble's criteria from 2000 (excluding head tremor in decubitus and compatible with the study by the investigator) * or with Parkinson's disease as defined by the United ...

Countries:France
Unlock Eligibility Criteria